Dexcom Looks To Expansion, Operational Efficiency For Rapid Growth
Executive Summary
Continuous blood glucose monitoring specialist Dexcom has seen its sales soar from $60m to over $700m within five years or so. Company president and CEO Kevin Sayer told Medtech Insight how the company is aiming to maintain this upward trajectory with a new addition to the leadership team, increased operational efficiency and expansion into new markets.
You may also be interested in...
Dexcom First To CGM Reimbursement Finish Line
Following a recent approval for their G5 continuous glucose monitor for use in children and adults without a finger stick, Dexcom has scored big with a new US Centers for Medicaid and Medicare Services policy that would make their CGM the first of its kind eligible for reimbursement from the agency.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.